张嘉杰，男，1967年生，博士，南方医科大学药学院研究员。
工作经历：
1996.07-1997.09第一军医大学药物研究所，实习研究员
1997.09-2004.08第一军医大学药物研究所，助理研究员
2004.08-2009.12南方医科大学药学院，副研究员
2009.12-南方医科大学药学院，研究员
2005.08-南方医科大学药学院，实验中心主任
2010.01-南方医科大学药学院，药物设计与合成学科PI
研究方向：
1.基于靶标结构的药物分子设计
2.创新药物合成及活性评价研究
主要科研课题：
1.广州市市重点研发计划项目,新型EGFRvⅢ抑制剂SMUZ106盐酸盐抗脑胶质瘤的临床前药理毒理学研究,2021.04-2024.03, 负责人
2.广东省自然科学基金项目，大环类4-三唑/咪唑-2-氨基吡啶/嘧啶骨架EGFR/EGFRvⅢ/JNK多靶点抑制剂的设计、合成及其抗脑胶质母细胞瘤作用,2021.01-2023.12, 负责人
3.国家自然科学基金项目，抗激酶区突变耐药的ROS1选择性抑制剂的设计、合成及活性研究，81573263，2016.01-2019.12，负责人
4.广东省科技计划项目，高活性间变性淋巴瘤激酶抑制剂SMU-B的成药性研究，2014A020210012，2015.06-2018.06，负责人
5.广东省自然科学基金项目，抗ALK/ROS1及其激酶区突变耐药的双重抑制剂的设计、合成与活性研究，2015A030313285，2015.08-2018.08，负责人
6.国家自然科学基金项目，新型VEGFR酪氨酸激酶抑制剂IPC-032对Wnt/β-catenin信号异常活化的结肠癌细胞合成致死效应的分子机理 81173097， 2012.01-2012.12，负责人
7.广东省科技厅国际合作项目，基于HIV gp41 融合多肽的新型抗艾滋病药物研究 2011B050200006，2010.01-2012.12年，负责人
8.广州市重大科技计划重大项目子课题，以受体酪氨酸激酶为靶点的新型抗肿瘤药物咪唑并吡啶类化合物的研究 2010U1-E00531-3，2010.09-2012.12，负责人
9.国家科技重大专项项目，新型抗肿瘤药物多靶点酪氨酸受体激酶抑制剂IPC-032的研究 ， 2009ZX09103-010，2009.01-2010.12，主要成员（第二）
10.广州市重大科技计划重大项目子课题，以受体酪氨酸激酶为靶点的新型抗肿瘤药物咪唑并吡啶类化合物的研究 2009A1-E011-8，2009.01-2010.08，负责人
11.广东省科技计划项目，相应于HIVgp41的多肽类HIV融合抑制剂C34的研究 2005A10904002，2005.01-2006.12，负责人
近三年主要论著：
1.Yang Z#, Yang H#, Ai Y, Zhang L, Li Z, Wan S, Xu X, Zhang H, Wu S, Zhang J*, Zhang T*， Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor，Eur J Pharm Sci. 2020;152:105463.
2.Jiang Y#, Yang Z#, Zhang L, Yan R, Liu S, Yang H, Wan S, Li Z, Zhu Z, Ye L*, Zhang J*, The cytochrome P450 metabolic profiling of SMU-B in vitro, a novel small molecule tyrosine kinase inhibitor，J Pharmaceut Biomed，2020，188:113400
3.Yang H#, Yan R#, Jiang Y, Yang Z, Zhang X, Zhou M, Wu X, Zhang T*, Zhang J*. Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance. Eur J Med Chem. 2019;187:111966.
4.Shanhe Wan, Ruohong Yan, Ying Jiang, Zhonghuang Li, Jiajie Zhang*, Xiaoyun Wu** Insight into Binding Mechanisms of EGFR Allosteric Inhibitors using Molecular Dynamics Simulations and Free Energy Calculations, J BIOMOL STRUCT DYN ,2019,37:16, 4384-4394
5.Liu S, Jiang Y, Yan R, Li Z, Wan S, Zhang T, Wu X, Hou J, Zhu Z, Tian Y, Zhang J*, Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors, Eur J Med Chem., 2019,179:358-375
6.Tian Y, Ma Y, Wu S, Zhang T, Li Z, Wang G, Zhang J*, Understand the acquired resistance of RTK inhibitors by computational receptor tyrosine kinases network. Comput Biol Chem. 2018 ,76:275-282.
7.Zhang T, Yang H, Yang Z, Tan S, Jin J, Liu S* ,Zhang J*, Sulfonated Compounds Bind with Prostatic Acid Phosphatase (PAP248-286) to Inhibit the Formation of Amyloid Fibrils. ChemistryOpen, 2018, 7(6):447-456
8.Wang Y#, Wan S#, Li Z, Fu Y, Wang G, Zhang J*, Wu X**, Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors. Eur J Med Chem. , 2018,155:210-228.
9.Liu S, Yang H, Jiang Y, Zhang T, Yan R, Zhang J*, Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. Future Med Chem. , 2018,10(14):1705-1720
10.Y Tian#, T Zhang#, L Long, Z Li, S Wan, G Wang, Y Yu, J Hou, X Wu*, J Zhang*, Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors, Eur J Med Chem, 2018,143:182-199.
11. Zhang T#, Tian Y#, Li Z, Liu S, Hu X, Yang Z, Ling X, Liu S*, Zhang J*, Molecular Dynamics Study to Investigate the Dimeric Structure of the Full-Length α-Synuclein in Aqueous Solution. J Chem Inf Model, 2017, 57(9):2281-2293.
12.Tian Y#, Yu Y#, Shen Y, Wan H, Chang S, Zhang T, Wan S, Zhang J*, Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK, J Chem Inf Model, 2017, 57:977−987.
一、近五年通讯作者发表论文：
1.Yang Z#, Yang H#, Ai Y, Zhang L, Li Z, Wan S, Xu X, Zhang H, Wu S, Zhang J*, Zhang T*， Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor，Eur J Pharm Sci. 2020;152:105463.
2.Jiang Y#, Yang Z#, Zhang L, Yan R, Liu S, Yang H, Wan S, Li Z, Zhu Z, Ye L*, Zhang J*, The cytochrome P450 metabolic profiling of SMU-B in vitro, a novel small molecule tyrosine kinase inhibitor，J Pharmaceut Biomed，2020，188:113400
3.Yang H#, Yan R#, Jiang Y, Yang Z, Zhang X, Zhou M, Wu X, Zhang T*, Zhang J*. Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance. Eur J Med Chem. 2019;187:111966.
4.Shanhe Wan, Ruohong Yan, Ying Jiang, Zhonghuang Li, Jiajie Zhang*, Xiaoyun Wu** Insight into Binding Mechanisms of EGFR Allosteric Inhibitors using Molecular Dynamics Simulations and Free Energy Calculations, J BIOMOL STRUCT DYN ,2019,37:16, 4384-4394
5.Liu S, Jiang Y, Yan R, Li Z, Wan S, Zhang T, Wu X, Hou J, Zhu Z, Tian Y, Zhang J*, Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors, Eur J Med Chem., 2019,179:358-375
6.Tian Y, Ma Y, Wu S, Zhang T, Li Z, Wang G, Zhang J*, Understand the acquired resistance of RTK inhibitors by computational receptor tyrosine kinases network. Comput Biol Chem. 2018 ,76:275-282.
7.Zhang T, Yang H, Yang Z, Tan S, Jin J, Liu S* ,Zhang J*, Sulfonated Compounds Bind with Prostatic Acid Phosphatase (PAP248-286) to Inhibit the Formation of Amyloid Fibrils. ChemistryOpen, 2018, 7(6):447-456
8.Wang Y#, Wan S#, Li Z, Fu Y, Wang G, Zhang J*, Wu X**, Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors. Eur J Med Chem. , 2018,155:210-228.
9.Liu S, Yang H, Jiang Y, Zhang T, Yan R, Zhang J*, Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. Future Med Chem. , 2018,10(14):1705-1720
10.Y Tian#, T Zhang#, L Long, Z Li, S Wan, G Wang, Y Yu, J Hou, X Wu*, J Zhang*, Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors, Eur J Med Chem, 2018,143:182-199.
11. Zhang T#, Tian Y#, Li Z, Liu S, Hu X, Yang Z, Ling X, Liu S*, Zhang J*, Molecular Dynamics Study to Investigate the Dimeric Structure of the Full-Length α-Synuclein in Aqueous Solution. J Chem Inf Model, 2017, 57(9):2281-2293.
12.Tian Y#, Yu Y#, Shen Y, Wan H, Chang S, Zhang T, Wan S, Zhang J*, Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK, J Chem Inf Model, 2017, 57:977−987.
13. XY Wu#* ,Y Fu , YY Wang , SH Wan , JJ Zhang*, Computational investigation on inhibition mechanism of BRAFV600E by Vemurafenib (PLX4032) and its analogue PLX4720, Med Chem Res, 2017, 26:390–396.
14. Xiaoyun Wu#*, Yuanyuan Wang, Shanhe Wan，Jiajie Zhang*, Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations, J BIOMOL STRUCT DYN, 2017, 2017:e1538
15. Fu Y, Wang Y, Wan S, Li Z, Wang G, Zhang J*, Wu X*, Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies, Molecules, 2017, 22: 542
16. Wu X#*, Fu Y, Wang Y, Wan S, Zhang J*, Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations, J Mol Model, 2017, 23:141.
17. Yu PJ, Wan LM, Wan SH, Chen WY, Xie H, Meng DM, Zhang JJ*, Xiao XL*, Standardized myrtol attenuates lipopolysaccharide induced acute lung injury in mice, Pharm Biol, 2016,54(12):3211-3216.
18. Hou J#, Wan S#, Wang G, Zhang T, Li Z, Tian Y, Yu Y, Wu X*, Zhang J*, Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor, Eur J Med Chem, 2016,118:276-289.
19. Wu X#*, Wan S, Wang G, Jin H, Li Z, Tian Y, Zhu Z, Zhang J*, Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2, J Mol Graph Model., 2015,56:103-112.
20. Tian Y, Shen Y, Zhang X, Ye L, Li Z, Liu Z, Zhang J*, Wu S, Design Some New Type-I c-met Inhibitors Based on Molecular Docking and Topomer CoMFA Research, Mol Inf, 2014, 33:536-543.
二、近五年主要专利：
1、2-氨基-4-取代吡啶衍生物及其合成方法和应用，申请号201910154274.9
2、3-（萘-1-甲基取代）吡啶衍生物及其合成方法及应用201810182722.1，PCT/CN2018/11584
3、3-(1-(氨基吡啶氧基乙基)苯甲酰胺衍生物及其合成方法和应用，申请号：201710059925.7
4、1-(2-氨基吡啶-4-基)-3-哌啶甲酰胺衍生物及其合成方法和应用， 申请号：201710237252.X授权
5、一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用，申请号：20171047293.8 授权
6、6-吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用，申请号：201610935466.X授权
7、2-氨基吡咯并[1,2-f][1,2,4]三嗪类化合物、合成方法及应用，申请号：201510259005.0，授权